Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis.

Palmowski A, Nielsen SM, Buttgereit T, Palmowski Y, Boers M, Christensen R, Buttgereit F.

Semin Arthritis Rheum. 2020 Mar 2. pii: S0049-0172(20)30069-X. doi: 10.1016/j.semarthrit.2020.02.016. [Epub ahead of print]

PMID:
32222381
2.

Views on glucocorticoid therapy in rheumatology: the age of convergence.

Buttgereit F.

Nat Rev Rheumatol. 2020 Apr;16(4):239-246. doi: 10.1038/s41584-020-0370-z. Epub 2020 Feb 19. Review.

PMID:
32076129
3.

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing.

Gaber T, Brinkman ACK, Pienczikowski J, Diesing K, Damerau A, Pfeiffenberger M, Lang A, Ohrndorf S, Burmester GR, Buttgereit F, Hoff P.

Int J Mol Sci. 2020 Jan 29;21(3). pii: E865. doi: 10.3390/ijms21030865.

4.

[Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases].

Freier D, Strehl C, Buttgereit F.

Hautarzt. 2020 Feb;71(2):139-153. doi: 10.1007/s00105-020-04543-0. German.

PMID:
31980858
5.

British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary.

Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B.

Rheumatology (Oxford). 2020 Mar 1;59(3):487-494. doi: 10.1093/rheumatology/kez664. No abstract available.

PMID:
31970410
6.

British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis.

Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B.

Rheumatology (Oxford). 2020 Mar 1;59(3):e1-e23. doi: 10.1093/rheumatology/kez672. No abstract available.

PMID:
31970405
7.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D.

Ann Rheum Dis. 2020 Jan 22. pii: annrheumdis-2019-216655. doi: 10.1136/annrheumdis-2019-216655. [Epub ahead of print]

8.

Glucocorticoids in rheumatoid arthritis: current status and future studies.

Hua C, Buttgereit F, Combe B.

RMD Open. 2020 Jan;6(1). pii: e000536. doi: 10.1136/rmdopen-2017-000536. Review.

9.

Spatial Distribution of Macrophages During Callus Formation and Maturation Reveals Close Crosstalk Between Macrophages and Newly Forming Vessels.

Stefanowski J, Lang A, Rauch A, Aulich L, Köhler M, Fiedler AF, Buttgereit F, Schmidt-Bleek K, Duda GN, Gaber T, Niesner RA, Hauser AE.

Front Immunol. 2019 Nov 26;10:2588. doi: 10.3389/fimmu.2019.02588. eCollection 2019.

10.

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.

Águeda AF, Monti S, Luqmani RA, Buttgereit F, Cid M, Dasgupta B, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt W, Hellmich B.

RMD Open. 2019 Sep 23;5(2):e001020. doi: 10.1136/rmdopen-2019-001020. eCollection 2019.

11.

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.

Monti S, Águeda AF, Luqmani RA, Buttgereit F, Cid M, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt W, Hellmich B.

RMD Open. 2019 Sep 16;5(2):e001003. doi: 10.1136/rmdopen-2019-001003. eCollection 2019.

12.

Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis.

March C, Huscher D, Preis E, Makowka A, Hoeppner J, Buttgereit F, Riemekasten G, Norman K, Siegert E.

Arch Rheumatol. 2019 Jan 28;34(3):253-261. doi: 10.5606/ArchRheumatol.2019.7111. eCollection 2019 Sep.

13.

Treat to Target: A Valid Concept for Management of Polymyalgia Rheumatica and Giant Cell Arteritis?

Camellino D, Dejaco C, Buttgereit F, Matteson EL.

Rheum Dis Clin North Am. 2019 Nov;45(4):549-567. doi: 10.1016/j.rdc.2019.07.005. Review.

PMID:
31564296
14.

[Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases].

Freier D, Strehl C, Buttgereit F.

Z Rheumatol. 2019 Oct;78(8):775-788. doi: 10.1007/s00393-019-00697-y. Review. German.

PMID:
31535201
15.

No association between participant retention and the proportion of included elderly people in rheumatology trials: Results from a series of exploratory meta-regression analyses.

Palmowski A, Nielsen SM, Buttgereit T, Palmowski Y, Boers M, Christensen R, Buttgereit F.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24051. [Epub ahead of print]

PMID:
31421022
16.

[Controlling glucocorticoid treatment in critically ill patients with rheumatism exemplified by systemic lupus erythematosus].

Freier D, Buttgereit F.

Z Rheumatol. 2019 Dec;78(10):947-954. doi: 10.1007/s00393-019-00686-1. Review. German.

PMID:
31410548
17.

Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System.

Strehl C, Ehlers L, Gaber T, Buttgereit F.

Front Immunol. 2019 Jul 24;10:1744. doi: 10.3389/fimmu.2019.01744. eCollection 2019. Review.

18.

Administration of Tramadol or Buprenorphine via the drinking water for post-operative analgesia in a mouse-osteotomy model.

Jirkof P, Durst M, Klopfleisch R, Palme R, Thöne-Reineke C, Buttgereit F, Schmidt-Bleek K, Lang A.

Sci Rep. 2019 Jul 24;9(1):10749. doi: 10.1038/s41598-019-47186-5.

19.

2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA.

Ann Rheum Dis. 2020 Jan;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672. Epub 2019 Jul 3.

PMID:
31270110
20.

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.

Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J.

RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019.

21.

Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial.

Hartman L, Bos R, Buttgereit F, Güler-Yuksel M, Ionescu R, Kok MR, Lems WF, Micaelo M, Opris-Belinski D, Pusztai A, Santos E, Da Silva J, Szekanecz Z, Zeiner K, Zhang D, Boers M.

Scand J Rheumatol. 2019 Jul;48(4):340-341. doi: 10.1080/03009742.2018.1559880. Epub 2019 May 27. No abstract available.

PMID:
31132016
22.

An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis.

Luís M, Freitas J, Costa F, Buttgereit F, Boers M, Jap DS, Santiago T.

Expert Opin Drug Saf. 2019 Jul;18(7):581-590. doi: 10.1080/14740338.2019.1615052. Epub 2019 May 14. Review.

PMID:
31056959
23.

Association between changes in molecular biomarkers of cartilage matrix turnover and changes in knee articular cartilage: a longitudinal pilot study.

Boeth H, Raffalt PC, MacMahon A, Poole AR, Eckstein F, Wirth W, Buttgereit F, Önnerfjord P, Lorenzo P, Klint C, Pramhed A, Duda GN.

J Exp Orthop. 2019 May 3;6(1):19. doi: 10.1186/s40634-019-0179-3.

24.

Hypoxia and mesenchymal stromal cells as key drivers of initial fracture healing in an equine in vitro fracture hematoma model.

Pfeiffenberger M, Bartsch J, Hoff P, Ponomarev I, Barnewitz D, Thöne-Reineke C, Buttgereit F, Gaber T, Lang A.

PLoS One. 2019 Apr 4;14(4):e0214276. doi: 10.1371/journal.pone.0214276. eCollection 2019.

25.

2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.

Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B, Dejaco C, Dixon WG, Feltelius N, Finckh A, Gilbert K, Mackie SL, Mahr A, Matteson EL, Neill L, Salvarani C, Schmidt WA, Strangfeld A, van Vollenhoven RF, Buttgereit F.

Ann Rheum Dis. 2019 Sep;78(9):1160-1166. doi: 10.1136/annrheumdis-2018-214755. Epub 2019 Mar 21. Review.

PMID:
30898837
26.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

27.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

28.

Metabolism of T Lymphocytes in Health and Disease.

Gaber T, Chen Y, Krauß PL, Buttgereit F.

Int Rev Cell Mol Biol. 2019;342:95-148. doi: 10.1016/bs.ircmb.2018.06.002. Epub 2018 Jul 18. Review.

PMID:
30635095
29.

Collagen I-based scaffolds negatively impact fracture healing in a mouse-osteotomy-model although used routinely in research and clinical application.

Lang A, Kirchner M, Stefanowski J, Durst M, Weber MC, Pfeiffenberger M, Damerau A, Hauser AE, Hoff P, Duda GN, Buttgereit F, Schmidt-Bleek K, Gaber T.

Acta Biomater. 2019 Mar 1;86:171-184. doi: 10.1016/j.actbio.2018.12.043. Epub 2019 Jan 5.

PMID:
30616076
30.

Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people.

Palmowski A, Buttgereit T, Palmowski Y, Nielsen SM, Boers M, Christensen R, Buttgereit F.

Semin Arthritis Rheum. 2019 Jun;48(6):983-989. doi: 10.1016/j.semarthrit.2018.10.017. Epub 2018 Nov 2.

PMID:
30466715
31.

CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells.

Gaber T, Schönbeck K, Hoff H, Tran CL, Strehl C, Lang A, Ohrndorf S, Pfeiffenberger M, Röhner E, Matziolis G, Burmester GR, Buttgereit F, Hoff P.

Int J Mol Sci. 2018 Aug 7;19(8). pii: E2312. doi: 10.3390/ijms19082312.

32.

Prevention of glucocorticoid morbidity in giant cell arteritis.

Buttgereit F, Matteson EL, Dejaco C, Dasgupta B.

Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii11-ii21. doi: 10.1093/rheumatology/kex459. Review.

PMID:
29982779
33.

The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend.

Palmowski Y, Buttgereit T, Buttgereit F.

Rheumatology (Oxford). 2019 Apr 1;58(4):580-587. doi: 10.1093/rheumatology/key169.

PMID:
29982743
34.

Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis.

Siegert E, March C, Otten L, Makowka A, Preis E, Buttgereit F, Riemekasten G, Müller-Werdan U, Norman K.

Nutrition. 2018 Nov;55-56:51-55. doi: 10.1016/j.nut.2018.03.046. Epub 2018 Apr 3.

PMID:
29960157
35.

[S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations].

Buttgereit F; DGRh, Brabant T; DGG, Dinges H; DGOOC, Hiemer I; Rheuma-Liga, Kaplani M; DGIM, Kiltz U, Kyburz D; SGR, Reißhauer A; DGPMR, Schneider M, Weseloh C, Dejaco C; ÖGR.

Z Rheumatol. 2018 Jun;77(5):429-441. doi: 10.1007/s00393-018-0476-8. Review. German.

PMID:
29845555
36.

[Osteoimmunology-IMMUNOBONE : Regulation of bone by inflammation].

Rauner M, Buttgereit F, Distler J, Garbe AI, Herrmann M, Hofbauer L, Hoffmann M, Jessberger R, Kornak U, Krönke G, Mundlos S, Spies C, Tuckermann J, Zwerina J.

Z Rheumatol. 2018 May;77(Suppl 1):12-15. doi: 10.1007/s00393-018-0455-0. Review. German. No abstract available.

PMID:
29691689
37.

Role of 11β-HSD type 1 in abnormal HPA axis activity during immune-mediated arthritis.

Sattler J, Tu J, Stoner S, Li J, Buttgereit F, Seibel MJ, Zhou H, Cooper MS.

Endocr Connect. 2018 Feb;7(2):385-394. doi: 10.1530/EC-17-0361. Epub 2018 Jan 31.

38.

In silico methods - Computational alternatives to animal testing.

Lang A, Volkamer A, Behm L, Röblitz S, Ehrig R, Schneider M, Geris L, Wichard J, Buttgereit F.

ALTEX. 2018;35(1):124-126. doi: 10.14573/altex.1712031. No abstract available.

39.

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.

Hartman L, Rasch LA, Klausch T, Bijlsma HWJ, Christensen R, Smulders YM, Ralston SH, Buttgereit F, Cutolo M, Da Silva JAP, Opris D, Rovenský J, Szamosi S, Middelink LM, Lems WF, Boers M.

Trials. 2018 Jan 25;19(1):67. doi: 10.1186/s13063-017-2396-3.

40.

Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review.

Safy M, de Hair MJH, Jacobs JWG, Buttgereit F, Kraan MC, van Laar JM.

PLoS One. 2017 Dec 21;12(12):e0188810. doi: 10.1371/journal.pone.0188810. eCollection 2017. Review.

41.

Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.

Albrecht K, Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, Thiele K, Zink A.

Rheumatol Int. 2018 Apr;38(4):569-577. doi: 10.1007/s00296-017-3874-3. Epub 2017 Nov 9.

PMID:
29124397
42.

Reply.

Palmowski Y, Buttgereit F, Boers M.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):577-578. doi: 10.1002/acr.23452. No abstract available.

43.

Unraveling the role of hypoxia-inducible factor (HIF)-1α and HIF-2α in the adaption process of human microvascular endothelial cells (HMEC-1) to hypoxia: Redundant HIF-dependent regulation of macrophage migration inhibitory factor.

Hahne M, Schumann P, Mursell M, Strehl C, Hoff P, Buttgereit F, Gaber T.

Microvasc Res. 2018 Mar;116:34-44. doi: 10.1016/j.mvr.2017.09.004. Epub 2017 Oct 6.

PMID:
28993199
44.

Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B.

Nat Rev Rheumatol. 2017 Oct;13(10):578-592. doi: 10.1038/nrrheum.2017.142. Epub 2017 Sep 14. Review.

45.

The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica.

Mackie SL, Twohig H, Neill LM, Harrison E, Shea B, Black RJ, Kermani TA, Merkel PA, Mallen CD, Buttgereit F, Mukhtyar C, Simon LS, Hill CL; OMERACT PMR Working Group.

J Rheumatol. 2017 Oct;44(10):1515-1521. doi: 10.3899/jrheum.161109. Epub 2017 Aug 1.

46.

Will we ever have better glucocorticoids?

Buttgereit F, Bijlsma JWJ, Strehl C.

Clin Immunol. 2018 Jan;186:64-66. doi: 10.1016/j.clim.2017.07.023. Epub 2017 Jul 27.

PMID:
28757452
47.

Inflammation Is an Important Covariate for the Crosstalk of Sleep and the HPA Axis in Rheumatoid Arthritis.

Straub RH, Detert J, Dziurla R, Fietze I, Loeschmann PA, Burmester GR, Buttgereit F.

Neuroimmunomodulation. 2017;24(1):11-20. doi: 10.1159/000475714. Epub 2017 May 24.

PMID:
28535535
48.

Glucocorticoids in rheumatoid arthritis: the picture is shaping up.

Buttgereit F, Bijlsma JW.

Ann Rheum Dis. 2017 Nov;76(11):1785-1787. doi: 10.1136/annrheumdis-2017-211187. Epub 2017 May 4. No abstract available.

PMID:
28473424
49.

Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study.

Cutolo M, Hopp M, Liebscher S, Dasgupta B, Buttgereit F.

RMD Open. 2017 Mar 17;3(1):e000426. doi: 10.1136/rmdopen-2016-000426. eCollection 2017.

50.

Metabolic regulation of inflammation.

Gaber T, Strehl C, Buttgereit F.

Nat Rev Rheumatol. 2017 May;13(5):267-279. doi: 10.1038/nrrheum.2017.37. Epub 2017 Mar 23. Review.

PMID:
28331208

Supplemental Content

Loading ...
Support Center